Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Refralon in Atrial Fibrillation/Flutter
NCT06540352Phase 2Active, not recruiting
- Start
- Jun 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of niferidil in Atrial fibrillation (AFib) and atrial flutter (AFL) (3 arms). Primary endpoint: Proportion of subjects maintaining sinus rhythm at 6 months. Started Jun 2024; status: active, not recruiting.
02
Drugs
niferidil
03
Conditions
Atrial fibrillation (AFib)atrial flutter (AFL)
Beyond the preview
Go deeper on NCT06540352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06540352.